Company SENN AB Nasdaq Stockholm
Equities
SE0010219626
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Genomic Allergen Rapid Detection
100.0
%
| 42 | 100.0 % | 50 | 100.0 % | +19.39% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 42 | 100.0 % | 50 | 100.0 % | +19.39% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 01/18/01 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 01/16/01 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 01/14/01 |
Director/Board Member | 59 | 15/14/15 | |
Public Communications Contact | 56 | 01/18/01 | |
Helen Olsson
HRO | Human Resources Officer | 59 | 01/20/01 |
Corporate Officer/Principal | 51 | 01/17/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 76 | 18/10/18 | |
Director/Board Member | 59 | 15/14/15 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 01/20/01 |
Director/Board Member | 65 | 01/20/01 | |
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 01/18/01 |
Ian Kimber
BRD | Director/Board Member | 74 | 01/15/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 24,188,325 | 14,889,392 ( 61.56 %) | 0 | 61.56 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-27.66% | 987.6Cr | |
+26.94% | 288.79Cr | |
-15.73% | 212.14Cr | |
-20.83% | 166.5Cr | |
+67.18% | 145.45Cr | |
+26.08% | 79Cr | |
-4.15% | 74Cr | |
-28.78% | 51Cr | |
+3.98% | 31Cr |